Investigational Drug Information for INCB054828
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for INCB054828?
INCB054828 is an investigational drug.
There have been 16 clinical trials for INCB054828.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 3rd 2019.
The most common disease conditions in clinical trials are Neoplasms, Carcinoma, and Cholangiocarcinoma. The leading clinical trial sponsors are Incyte Corporation, National Cancer Institute (NCI), and Academic and Community Cancer Research United.
There are four US patents protecting this investigational drug and one hundred and thirty-eight international patents.
Summary for INCB054828
| US Patents | 4 |
| International Patents | 138 |
| US Patent Applications | 71 |
| WIPO Patent Applications | 109 |
| Japanese Patent Applications | 14 |
| Clinical Trial Progress | Phase 2 (2019-06-03) |
| Vendors | 25 |
Recent Clinical Trials for INCB054828
| Title | Sponsor | Phase |
|---|---|---|
| The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies. | Incyte Corporation | Phase 2 |
| Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma | National Cancer Institute (NCI) | Phase 1 |
| Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma | Academic and Community Cancer Research United | Phase 1 |
Clinical Trial Summary for INCB054828
Top disease conditions for INCB054828
Top clinical trial sponsors for INCB054828
US Patents for INCB054828
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| INCB054828 | See Plans and Pricing | Substituted tricyclic compounds as FGFR inhibitors | Incyte Corporation (Wilmington, DE) | See Plans and Pricing |
| INCB054828 | See Plans and Pricing | Heterocyclic compounds as immunomodulators | Incyte Corporation (Wilmington, DE) | See Plans and Pricing |
| INCB054828 | See Plans and Pricing | Heterocyclic compounds as immunomodulators | Incyte Corporation (Wilmington, DE) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for INCB054828
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| INCB054828 | Argentina | AR091424 | 2032-06-13 | See Plans and Pricing |
| INCB054828 | Argentina | AR117823 | 2032-06-13 | See Plans and Pricing |
| INCB054828 | Australia | AU2013287176 | 2032-06-13 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
